Absorbed doses to tumor xenografts and normal tissues. Cumulated activities were calculated from biodistribution curves and multiplied with the mean energy of the α particles from ²²⁷Th or from ²²³Ra and daughters in order to estimate the absorbed dose after injection of ²²⁷Th-p-benzyl-DOTA-rituximab (A) or ²²⁷Th-p-benzyl-DOTA-trastuzumab (B). For ⁹⁰Y-ibritumomab-tiuexetan (C), cumulated activities were calculated from the biodistribution curves of ¹²⁵I-ibritumomab-tiuexetan adjusted for decay of ¹²⁵I. The activities of ²²⁷Th-p-benzyl-DOTA-rituximab and ²²⁷Th-p-benzyl-DOTA-trastuzumab were normalized to an injection of 200 kBq/kg and the activities of ⁹⁰Y-ibritumomab-tiuexetan were normalized to an injection of 15 MBq/kg. Data are mean (± SE).